Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol for cannabis use disorder
ACTRN12623000526673Phase 3Completed
- Sponsor
- University of Sydney
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cannabis use disorder (CUD) comparing Epidyolex with Placebo (2 arms). Primary endpoints: Cannabis-free days at week 24 and Urinary THC-COOH at week 24. Started May 2024; status: completed.
02
Drugs
cannabidiol
03
Conditions
cannabis use disorder (CUD)
Beyond the preview
Go deeper on ACTRN12623000526673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623000526673.